Physician profile
Ella Williamson
NPI 1740568443
$1,411.56
in general payments reported to CMS, 2019-2025
9 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $177 · 2022: $264 · 2023: $217 · 2024: $464 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $312.72 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $243.73 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $229.77 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $194.67 | 2022-2025 | Abilify Maintena |
| Abbvie INC. | $192.53 | 2021-2025 | |
| Alkermes, INC. | $145.09 | 2022-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $52.08 | 2021-2025 | Uzedy |
| Bioxcel Therapeutics, INC. | $22.88 | 2023 | Igalmi |
| Neurocrine Biosciences, INC. | $18.09 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ella Williamson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.